BioSpace News Archive

Fulcrum Therapeutics, Inc. today announced that the Company granted non-statutory stock options to new employees.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for May 2023.

Golden Biotechnology Corp. announces the release of positive interim results from its Phase II clinical trial of Antroquinonol in combination with the standard of care nab-paclitaxel + gemcitabine for first-line treatment of metastatic pancreatic cancer.

Mallinckrodt plc is pleased to announce it has received an award from the NORD, recognizing it as an “Industry Innovator” for the creation of a treatment “to improve the lives of rare disease patients.” Mallinckrodt is being recognized for the U.S. FDA approval of TERLIVAZ® for injection for the treatment of adults with HRS with rapid reduction in kidney function.

It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO, Lisa Yañez suddenly passed away on Tuesday, May 2, 2023.

Arvinas, Inc. today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Ginkgo Bioworks Holdings, Inc.today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer (“CAO”), effective May 15, 2023.

WELL Health Technologies Corp. is pleased to announce the Company will release its First Quarter 2023 financial results for the period ended March 31, 2023, on Friday, May 12, 2023.

Aditxt®, Inc. today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases.

Fulgent Genetics, Inc. today announced financial results for its first quarter ended March 31, 2023.